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Abstract
Background Autoimmune hepatitis (AIH) is an immune-
mediated liver disease of unknown etiology. Increasing
incidence of AIH in Asian patients has been reported.
However, the phenotypic difference of Asian patients in
Europe and Asia has still not been explored.
Aim To evaluate the clinical presentation, biochemical
and immunological profiles, treatment response and sur-
vival outcome of type 1 AIH from two tertiary liver
transplant centres (United Kingdom and Singapore).
Method Patients who fulfilled the simplified diagnostic
scoring criteria of AIH were included in the study. Patients
with overlap syndrome were excluded.
Results Totals of 40 Asian patients and 159 Caucasian
patients from the University Hospital of Birmingham
National Health Service Foundation Trust, UK, were com-
pared with 57 Asian patients from Singapore General
Hospital, Singapore. Asian patients from Singapore present
significantly much later (median 55 vs. 32 years, p\ 0.001),
had higher MELD (p\ 0.001) with lower albumin
(p\ 0.001) and higher bilirubin (p\ 0.001) and lower
ASMA positivity (p\ 0.001) at diagnosis compared to UK
Asian. Jaundice at presentation was much higher in Singa-
pore Asian patients compared to UK Asian (53 vs. 30 %) but
cirrhosis at diagnosis was more common in UK patients.
Associated autoimmune conditions were less commonly seen
in Singapore Asians. Comparing between UK cohorts, Asian
patients present at younger age and have higher IgG level
compared to Caucasian. Overall, 5-year transplant-free sur-
vival in all three cohorts was similar (p = 0.846).
Conclusion We demonstrate that AIH patients from
Singapore present at older age with jaundice and have a
low positivity of SMA. Despite these differences, trans-
plant-free survival is similar in the two groups.
Keywords Autoimmune hepatitis  Asian  Caucasian 
Ethnicity  Clinical features  Immunology  Survival
Introduction
Autoimmune hepatitis (AIH) is an immune-mediated liver
disease of an unknown etiology with female preponderance
[1]. It is a rare disease with a prevalence of 10–17 per
100,000 populations in Europe and a mean incidence of
1–2 per 100,000 person-years [1, 2]. Type 1 AIH is char-
acterised by the presence of anti-nuclear antibodies (ANA)
and anti-smooth muscle antibodies (ASMA) in serum and it
affects all ages, although the majority of cases are seen
mainly in adults [1, 3]. AIH is commonly associated with
other autoimmune conditions.
It has been reported that ethnicity has an impact on the
prevalence, clinical presentations, and the natural history of
type 1 AIH [4–6]. Ethnicity-related prevalence of AIH was
found to be significantly lower in Asians who reside in
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New Zealand when compared to Caucasians, despite being
exposed to the same environment [7]. A previous study
described that AIH in patients of African ethnicity pre-
sented with more aggressive disease at clinical presenta-
tion, were less likely to respond to conventional
immunosuppressive treatment and resulted in worse liver
morbidity-related outcomes compared to Caucasians [8].
Asian-American AIH patients also demonstrated more
aggressive disease with poorer survival, and Hispanic
populations had a higher prevalence of biopsy-proven cir-
rhosis at presentation compared to Caucasians [9]. A study
in the UK in 2002 showed that non-European Caucasians
(African, Asian and Arabic) presented with more severe
forms of liver disease in all aspects with international cri-
teria for a diagnosis of AIH, and they seemed to require
higher levels of immunosuppression from earlier points
after diagnosis [10]. Another study by Verma et al. [8]
mentioned that black ethnicity, especially men, have more
aggressive disease, and that they are less likely to respond
to standard immunosuppression with a worse outcome than
non-black ethnicity. Taken together, these reports suggest
that ethnicity has an impact on the natural history of AIH.
In this study, we aim to investigate the difference in
natural history, mode of presentation, immunological pro-
files, associated autoimmune diseases, response to
immunosuppression and survival outcomes of Asian type 1
AIH who reside in two different continents; namely the
United Kingdom (UK) and Singapore. In addition, we
compare a Caucasian patient cohort to an Asian cohort
within the same hospital in the UK.
Patients and methods
Study cohort
The details of patients with type 1 AIH who attended liver
outpatients at two tertiary liver transplant centres: Univer-
sity Hospital of Birmingham, UK, and Singapore General
Hospital, Singapore, were retrospectively collected and
analysed. Data was obtained between the years 1995 and
2015 in the UK and between 2001 and 2014 in Singapore.
The UK cohorts were drawn from 203 patients with type
1 AIH. Of these, 40 patients of Asian ethnicity were
included in the study and compared with 57 patients from
Singapore. An additional cohort of 159 Caucasian patients
from the same UK hospital was also compared to the UK
Asian cohort. The remaining four patients from the UK
were of different ethnicities and were not considered in this
analysis. The total duration of follow-up was 10 years
(median of 4 years, range 1 month to 18 years) for the UK
patient cohort and 14 years for the Singapore patient cohort
(median of 4 years, range 1 month to 11 years).
All patients were evaluated and diagnosedwith type 1 AIH
by hepatologists within our medical centres based on clinical,
biochemical, and immunological parameters along with liver
histology. All liver biopsies were reviewed and reported by
dedicated liver histopathologists. Patients with a simplified
AIH score of greater than or equal to six were included in the
study. Patients with overlap syndrome (primary biliary cir-
rhosis or primary sclerosing cholangitis with type 1 AIH)
were excluded from the study. Other liver conditions, such as
metabolic liver diseases, viral hepatitis, alcoholic or non-al-
coholic fatty liver diseases, were also excluded.
Data were collected thoroughly from electronic case
notes, clinical letters and treatment charts. Demographics
data, clinical presentations, blood parameters such as bio-
chemistry and immunology, liver histology and the pres-
ence of other associated autoimmune conditions were
documented. Treatment of autoimmune hepatitis such as
usage of the steroid, azathioprine, other second-line
immunosuppression and liver-related complications such
as decompensation and development of hepatocellular
carcinoma were also documented.
Statistical analysis
Comparisons were made between the UK Asian cohort and
both the Singapore Asian and UK Caucasian cohorts. Since
the UK Asian cohort was included in both these analyses,
all p values were Bonferroni-adjusted for two comparisons,
to help control the type 1 error rate.
Dichotomous variables were compared between the
cohorts using Fisher’s exact tests, with ordinal and continuous
variables assessed usingMann–Whitney tests, and reported as
medians and interquartile ranges (IQRs). The number of flare-
ups were converted into rates per patient-year, in order to
account for the differences in follow-up durations between the
patients, with comparisons between the cohorts performed
using the OpenEpi calculator [11]. Transplant-free survival
was assessed using Kaplan–Meier curves, with a log-rank test
used to compare between the cohorts.
All analyses were performed using IBM SPSS Statistics
22 (IBM, Armonk, NY, USA), with the exception of the
comparison of flare-up rates. Patients with missing data were
excluded on a per-analysis basis and p\ 0.05 was deemed
to be indicative of statistical significance throughout.
Results
Comparison between UK Caucasian and UK Asian
AIH patient cohorts
A total of 159 Caucasian patients were compared against
40 Asian patients from the same hospital in the UK. The
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details of the comparison are shown in Tables 1 and 2. The
majority of the patients were female (79 % in Caucasian
vs. 75 % in Asian, p = 1.000), with Caucasian patients
presenting with the disease at significantly later ages than
Asians (median age of 51 vs. 32 years, p\ 0.001). BMI
was similar in the two groups, with a median of 26.2 in
Caucasian versus 26.0 in Asian (p = 0.556). No significant
differences were detected between the groups in the rates
of hypertension (p = 0.648), type 2 diabetes (p = 0.442)
or hypercholesterolemia (p = 0.776).
The most commonly observed type of associated
autoimmune conditions were connective tissue disorders,
(vasculitis, systemic lupus erythromatus, limited sclero-
derma, Sjogren’s disease, vitiligo, psoriasis or rheumatoid
disorder), which affected similar proportions of Asians and
Caucasians (18 vs. 21 %, p = 1.000). The only type of
associated autoimmune conditions that differed signifi-
cantly by ethnicity was those that were haematology-
related (e.g. autoimmune hemolytic thrombocytopenia or
autoimmune hemolytic anemia), which were present in
15 % of Asians, compared to 3 % of Caucasian patients
(p = 0.020).
Rates of liver biopsy at the time of diagnosis were
similar in the Asian and Caucasian groups (73 vs. 75 %,
p = 1.000), as were the rates of cirrhosis (40 vs. 51 %,
p = 0.576). Hepatocellular carcinoma was uncommon in
both cohorts, with no cases in Asian patients and only 3
(2 %) in Caucasians. Around 10 % of patients in both
cohorts presented with features of liver decompensation
such as ascites, hepatic encephalopathy or variceal bleed at
the time of diagnosis. The proportions of patients pre-
senting with jaundice were similar in both groups (21 in
Caucasian vs. 30 % in Asian, p = 0.424). The models for
end-stage liver disease (MELD) score were also similar in
the two cohorts (median 6 in Caucasian vs. 7 in Asian,
p = 0.324). At diagnosis, both Caucasian and Asian
Table 1 Demographic and clinical comparison between the three cohorts
Factor UK Asian
(n = 40)
Singapore Asian
(n = 57)
p value* UK Caucasian
(n = 159)
p value**
Demographics
Age at start of follow-up 32.0 (22.0–52.4) 55.0 (50.0–64.0) <0.001 50.5 (28.9–60.3) 0.002
Gender (female) 30 (75 %) 49 (86 %) 0.386 125 (79 %) 1.000
Body mass index 26.0 (22.3–28.0) 24.7 (21.2–28.1) 0.580 26.2 (23.4–31.5) 0.556
Biopsied at diagnosis 29 (73 %) 56 (98 %) <0.001 119 (75 %) 1.000
Cirrhosis at diagnosis 16 (40 %) 12 (23 %) 0.154 81 (51 %) 0.576
Hepatocellular carcinoma 0 (0 %) 1 (2 %) 1.000 3 (2 %) 1.000
Hypertension 8 (20 %) 24 (42 %) 0.058 45 (28 %) 0.648
Type two diabetes 9 (23 %) 10 (18 %) 1.000 22 (14 %) 0.442
Hypercholesterolemia 3 (8 %) 16 (28 %) 0.036 6 (4 %) 0.776
Clinical presentation
Jaundice 12 (30 %) 30 (53 %) 0.074 33 (21 %) 0.424
Decompensated at diagnosis 4 (10 %) 2 (4 %) 0.452 15 (9 %) 1.000
Bloods at diagnosis
Albumin 40 (31–43) 31 (27–35) <0.001 39 (34–43) 1.000
Bilirubin 19 (11–38) 49 (18–172) <0.001 20a (11–38) 1.000
INR 1.1 (1.0–1.3) 1.2 (1.1–1.3) 0.606 1.1 (1.0–1.2) 0.636
Model for end stage liver disease (MELD) 7 (6–10) 13 (9–18) <0.001 6 (6–10) 0.324
Other autoimmune conditions
Any gastro-intestinal 5 (13 %) 0 (0 %) 0.020 12 (8 %) 0.688
Any connective 7 (18 %) 6 (11 %) 0.746 33 (21 %) 1.000
Any endocrine 3 (8 %) 1 (2 %) 0.606 19 (12 %) 1.000
Any renal 2 (5 %) 0 (0 %) 0.336 1 (1 %) 0.208
Any haematology 6 (15 %) 1 (2 %) 0.036 5 (3 %) 0.020
Continuous variables are reported as medians and interquartile ranges, with numbers and rates quoted otherwise
p values are post hoc comparisons between the UK Asian * Singapore Asian or ** UK Caucasian cohorts. Mann–Whitney tests and Fisher’s
exact tests were used, as applicable, with Bonferroni adjustment for two comparisons applied to the resulting p values. p values significant at
p\ 0.05 are shown in bold
a Based on n = 32, due to missing data
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patients had comparable levels of albumin (median 39 vs.
40, p = 1.000), bilirubin (20 vs. 19, p = 1.000) and INR
(1.1 vs. 1.1, p = 0.636).
The majority of the patients had anti-nuclear antibody
positivity at diagnosis, followed by positive anti-smooth
muscle antibody (ASMA) and anti-neutrophil cytoplasmic
antibodies (ANCA), with all three having similar rates in
both groups. Immunoglobulin-G (Ig G) was found to be
significantly higher in Asian cohort (median 21.9 vs. 17.8,
p = 0.032).
The majority of the patients in both groups were started
on steroids followed by azathioprine (AZA) and
mycophenolate mofetil (MMF), with the treatment rates in
both groups being similar (all, p = 1.000). There were only
around a 20 % point reduction in use of steroids in both
cohorts from the time of diagnosis to the most recent fol-
low-up. The proportion of patients for whom there were
concerns about compliance was 9 % in Caucasians and
15 % in Asians (p = 0.770). The documented number of
flare-ups per year were low in both groups during follow-
up (0.24 vs. 0.33 episodes per patient year). Transplant-free
survival was also similar in the two groups, with rates at
5 years of 88 % in Caucasians compared to 84 % in
Asians, (p = 1.000, Fig. 1).
Comparison between UK Asian and Singapore
Asian cohort of AIH patients
The 40 UK Asian patients were then compared to a cohort
of 57 Asian patients from Singapore. The Singapore cohort
presented at a significantly older age than the UK Asians
(median 55 vs. 32 years, p\ 0.001), and were significantly
more likely to be biopsied at diagnosis (98 vs. 73 %,
p\ 0.001). No significant differences were detected in the
gender (p = 0.386) or BMI (p = 0.580) distributions of
the cohorts nor in the rates of type 2 diabetes (p = 1.000).
However, Singapore Asians had significantly higher rates
of hypercholesterolemia (28 vs. 8 %, p = 0.036) than UK
Asians. Jaundice (53 vs. 30 %, p = 0.074) and hyperten-
sion (42 vs. 20 %, p = 0.058) were also more common in
Singapore Asians, although not significantly so.
Of the blood work taken at diagnosis, the patients from
Singapore had significantly lower albumin (median 31 vs.
40, p\ 0.001), and significantly higher bilirubin (49 vs.
19, p\ 0.001) and MELD (13 vs. 7, p\ 0.001) than
Asians from the UK. Associated autoimmune conditions
were less commonly seen in Singapore Asians, with sig-
nificantly lower rates of gastro-intestinal- (0 vs. 13 %,
p = 0.020) and hematology-related (2 vs. 15 %,
Table 2 Comparison between UK Caucasian and UK Asian: Immunology and treatment
Factor UK
Asian
(n = 40)
Singapore Asian
(n = 57)
p value* UK Caucasian
(n = 159)
p value**
Immunology profile
Anti-nuclear antibody 32 (80 %) 53 (93 %) 0.134 121 (76 %) 1.000
Anti-neutrophil cytoplasmic antibody 5 (13 %) 2 (4 %) 0.248 30 (19 %) 1.000
Anti-smooth muscle (type 1) antibody 29 (73 %) 16 (28 %) <0.001 125 (79 %) 0.810
Soluble liver antigen 0 (0 %) 1 (2 %) 1.000 0 (0 %) 1.000
Ig G 21.9 (15.5–30.6) 25.0 (16.7–33.3) 0.832 17.8 (12.7–24.7) 0.032
Ig M 1.9 (1.2–2.5) 1.5 (1.1–3.1) 1.000 1.6 (1.1–2.5) 0.700
Ig A 4.0 (2.1–5.2) 4.1 (3.2–5.6) 0.342 2.9 (1.9–4.3) 0.079
Medications at diagnosis
Steroids 37 (93 %) 55 (98 %) 0.610 135 (85 %) 0.604
Azathioprine 20 (50 %) 19 (33 %) 0.282 79 (50 %) 1.000
Mycophenolate mofetil 6 (15 %) 0 (0 %) 0.008 12 (8 %) 0.424
Current medications
Steroids 30 (75 %) 36 (63 %) 0.542 109 (69 %) 1.000
Azathioprine 25 (63 %) 19 (33 %) 0.014 91 (57 %) 1.000
Mycophenolate mofetil 7 (18 %) 0 (0 %) 0.003 28 (18 %) 1.000
Number of flare-ups (per patient-year)a 0.33a (0.26–0.41) 0.22a (0.17–0.29) 0.062a 0.24a (0.22–0.28) 0.060a
Concerns with compliance 6 (15 %) 0 (0 %) 0.008 15 (9 %) 0.770
Continuous variables are reported as medians and interquartile ranges, with numbers and rates quoted otherwise
p values are post hoc comparisons between the UK Asian and * Singapore Asian or ** UK Caucasian cohorts. Mann–Whitney tests and Fisher’s
exact tests were used, as applicable, with Bonferroni adjustment for two comparisons applied to the resulting p values. p values significant at
p\ 0.05 are shown in bold
a Reported as rates per patient-year and 95 % confidence intervals, with p values from the mid-P exact test
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p = 0.036) conditions than Asians from the UK. Analysis
of the immunological profiles of the two groups generally
found no significant differences, with the exception of anti-
smooth muscle antibody, which was detected in 28 % of
Singapore Asians, compared to 73 % of those from the UK
(p\ 0.001).
Steroid usage was similar in the two groups at baseline
(Singapore: 98 vs. UK: 93 %, p = 0.610) and the most
recent follow-up (75 vs. 63 %, p = 0.542). Azathioprine
was less commonly used in Singapore, with usage rates of
33 versus 50 % (p = 0.282) at diagnosis, and 33 versus
63 % (p = 0.014) at the most recent follow-up. None of
the Singapore Asians used MMF, compared to 15 % of UK
Asians at diagnosis and 18 % at the most recent follow-up
(p = 0.008, 0.003). There were no concerns with compli-
ance in the Singapore cohort, compared to 15 % of the UK
Asian cohort (p = 0.008).
Transplant-free survival was similar in the two groups
(p = 1.000), with rates at 5 years of 93 % in Singapore and
84 % in UK Asians (p = 1.000, Fig. 1). Flare-up rates
were low in both groups, with an average of 0.22 per
patient-year in Singapore Asians, compared to 0.33 in
those from the UK (p = 0.062).
Discussion
Ethnic difference has been reported to have an impact on
the natural history of AIH [4–6, 8, 12]; however, the dif-
ference in clinical phenotype of Asian patients between
different continents is still unexplored. In this study, we
demonstrated differences in age at initial diagnosis, clinical
presentation, immunology profiles, associated autoimmune
conditions, immunosuppression used and treatment
response/compliance, between Asian type 1 AIH patients
in UK and Singapore.
Autoimmune hepatitis could present at any age but
generally peaks around puberty and between the 4th and
6th decades in adult life [6, 13]. In our study, UK Cau-
casian patients presented at a significantly later age com-
pared to the UK Asian population. From the comparisons
with the Singapore Asian cohort, we observed that the UK
Asian patients’ cohort presented earlier, on an average
during their 3rd decade, compared to the 5th decade of the
cohort from Singapore. This later presentation may explain
the reason of higher incidence of hypertension and hyper-
cholesterolemia in the Singapore Asian AIH cohort. AIH
patients are generally asymptomatic, and diagnosis was
made from routine blood tests, although jaundice at initial
presentation is not uncommon. Interestingly, we noted that
Singapore Asian patients commonly presented with jaun-
dice, and had significant higher levels of bilirubin, a higher
MELD score, and lower levels of albumin at diagnosis.
Immunological parameters such as hyperglobulinemia
and positive autoantibodies are crucial for the diagnosis of
type 1 AIH [14]. Type 1 AIH is characterised by the
presence of ANA and/or SMA, although 19 % of AIH
patients may not have any evidence of serological posi-
tivity at the time of presentation [15]. Low levels of SMA
positivity have been previously described in Asian patients
with type 1 AIH [16] and we have seen that in our Sin-
gapore Asian cohort. A large proportion of UK-Asian
patients in our study were cirrhotic (40 %), thus there was a
potential early onset of disease in the UK cohort, which
may be attributable to a higher index of diagnosis related to
higher SMA positivity on immunological investigation.
UK Caucasian patients expressed lower levels of Ig-G
compared to the Asian cohort, and were less likely to have
associated hematological autoimmune conditions. None of
the other factors compared between UK Asian and UK
Caucasian were found to differ significantly, including
transplant-free survival.
In addition, associated autoimmune diseases such as
coeliac disease and inflammatory bowel disease are more
common in UK Asian patients than those from Singapore.
Previous observations have suggested that Th17 cells and
memory mucosa lymphocytes are involved in gut–liver
axis immunology [17, 18], and the high prevalence of
inflammatory bowel disease in western countries may be
the reason for the association.
Despite the availability of effective treatment, AIH is
not a benign condition, with recent long-term studies
reporting a twofold higher mortality than that of the general
population [19, 20]. The majority of patients with AIH
usually respond to standard immunosuppressive therapy
Fig. 1 Kaplan–Meier survival curves of all study cohorts
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with steroids and azathioprine [AZA] [21], which we
observed in our cohort. Around 80 % of patients achieved
remission with standard immunosuppressive therapy [22,
23], while 10–15 % of patients do not achieve biochemical
remission with these standard therapies [24–26]. Alterna-
tive immunosuppression such as MMF could be used for
those who cannot tolerate AZA [27]. Our study found that
MMF was used as second-line therapy only in UK patients.
All patients from Singapore tend to be controlled by stan-
dard immunosuppression with steroids and azathioprine.
End-stage liver cirrhosis related to AIH accounts for
4–6 % of adult liver transplantation in Europe and the
United States [28, 29]. Of patients with AIH, 23 % from
Singapore and 40 % of Asians and 51 % of Caucasians in
the UK were cirrhotic at the time of presentation. Wong
and colleagues reported that AIH in Asian patients who
reside in United States tend to present with more aggres-
sive states and patients are cirrhotic at the time of pre-
sentation [30]. In our study, the index incidence of cirrhosis
at diagnosis was higher among UK Asian patients, which
may be related to earlier onset or a high index of suspicion
or early referral of this group to tertiary transplant centres.
Wong et al. [30] also suggested that INR tends to be higher
in Asian population. However, we did not notice any differ-
ence in albumin titre and INR between the UK Asians and
Caucasians in our study, as the majority of cases are com-
pensated Child-Pugh grade A cirrhosis. Only 10 % of UK
Asian patients and 4 % of Singapore patients presented with
decompensated liver disease. It is possible that differences in
health care provision between different studies may have
impacted on the synthetic function and timing of presenta-
tion. Long-term liver-related morbidity such as decompen-
sation or hepatocellular carcinoma incidence of both groups
remained similar. Higher MELD score was observed in
Singapore Asian patients, which could be related to higher
bilirubin in this cohort, as the initial presentation inmore than
half of this cohort was with jaundice. Our study importantly
demonstrated similar transplant-free survival in both groups.
We have identified a few limitations associated with our
study, mainly due to the nature of retrospective and
descriptive studies. First, we compared our UK Asians with
Singapore Asians. The majority of UK Asian cohorts were
of Indian origin while Singapore Asians were of Far East
origin. Secondly, our cohort might represent AIH patients
with more severe disease since we were tertiary liver
transplant centres. Diet might also play an important role in
differences between our cohorts. There is a population-
based study conducted in New Zealand [31] that showed
alcohol consumption was associated with a lower risk of
diagnosing with AIH, but individuals who were vegetarian
for more than a year and had antibiotics usage within
12 months before AIH diagnosis were significant risk
factors associated with AIH.
In conclusion, our data suggested that AIH patients from
Singapore present at older age with jaundice and have a
low positivity of SMA with similar survival outcomes.
These findings highlight that future work is required to
explore the ethnicity-related epigenetic, microbiome,
environmental and dietary factors for further understanding
of AIH immunopathogenesis. We aim to conduct a large
number multiple-centre study in the near future to have a
better understanding of the impact of ethnicity in autoim-
mune hepatitis.
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